Pharma Business - December 17, 2015
AstraZeneca makes strategic investment in China
AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced a range of strategic initiatives to accelerate the delivery of innovative biologics and targeted medicines to patients in China, the company’s second largest market globally and a key growth platform. The initiatives and investments include: * A strategic alliance with WuXi AppTec, a […]
Acquisition - December 17, 2015
AstraZeneca buys most of Acerta for $4 billion
AstraZeneca has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The transaction provides AstraZeneca with an irreversible oral Bruton’s tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), currently in Phase III development for B-cell blood cancers and in Phase I/II clinical […]
Acquisition - December 15, 2015
AstraZeneca acquires Takeda’s respiratory business
AstraZeneca has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD). AstraZeneca […]
Agreement - November 27, 2015
Pelago Bioscience, AstraZeneca enter agreement
Pelago Bioscience AB and AstraZeneca have entered into a 2-year strategic research collaboration and license agreement. The companies will collaborate on specified joint projects and AstraZeneca will also be granted a license to use and apply the Cellular Thermal Shift Assay (CETSA®) for determination and quantification of drug–target interactions in other AstraZeneca discovery projects. During the […]
Acquisition - November 1, 2015
AstraZeneca acquires ZS Pharma
AstraZeneca has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ion-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure […]
Pharma Business - October 26, 2015
AstraZeneca opens manufacturing site in Russia
AstraZeneca will open a new manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines. In 2011 AstraZeneca was one of the first multinational pharmaceutical companies to announce plans to invest in the construction of a dedicated manufacturing facility in Russia. Four years on, the company has invested $224m in […]
